Press

Optimi Health Provides Progress Report On Year Of Commercialization

Sep 1 • 4 min read

Optimi Health Corp.(CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets, is pleased to provide an operational update on the progress of its planned year of…

Filament Health and ATMA Journey Centers Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial

Sep 1 • 3 min read

Filament Health Corp (OTCQB: FLHLF | NEO: FH) (FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and ATMA Journey Centers, a company focused on delivering effective and innovative experiences that leverage the potential of psychedelic medicine, today announced the recent dosing of 14 healthy subjects with Filament’s natural psilocybin drug candidate in a Health…

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 31 • 4 min read

Bright Minds Biosciences (Nasdaq: DRUG | CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I trial for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications….

PharmAla Biotech to Supply University of Sydney Clinical Trial with LaNeo™ MDMA

Aug 31 • 2 min read

PharmAla Biotech (CSE: MDMA) is proud to have been selected as the MDMA manufacturing partner for the University of Sydney’s upcoming Phase 2 Clinical Trial. Founded in 1850, The University of Sydney is one of the top universities in Australia There is a high rate of comorbidity between alcohol use disorders and Post Traumatic Stress Disorder which is associated with…

PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022

Aug 31 • 4 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic sector through its flagship platform, Psychedelic Spotlight, completed and published its 2021 Audited Financials. The accomplishment comes after PSYC completed its 2020 Audited Financials in March, representing an important milestone as it works towards becoming a fully current SEC reporting company and up listing to the OTCQB. Following the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435